TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01911429
Drug: Placebo 40 or 80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 40 or 80 mg once daily
Study: NCT04488900
Drug: Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04488900
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01790308
Drug: CSII
Normalized name: Continuous Subcutaneous Insulin Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous subcutaneous insulin infusion for 2\~4 weeks
Study: NCT01035515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose oral capsule placebo comparator
Study: NCT01035515
Drug: BIIB014 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose oral capsule 50mg BIIB014
Study: NCT01035515
Drug: BIIB014 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose oral capsule 100mg BIIB014
Study: NCT00793598
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01853176
Drug: Standard bupivicaine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00218322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.
Study: NCT03709160
Drug: Bumetanide 1 MG
Normalized name: bumetanide 1 MG
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: all patients will be taking the treatment recommended by heart failure guidelines
Study: NCT06083116
Drug: Hydrochlorothiazide、Henagliflozin Proline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide and Henagliflozin Proline
Study: NCT00435292
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nonsteroidal anti-inflammatory drug
Study: NCT02230930
Drug: Subcutaneous hydrocortisone 10mg
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous hydrocortisone 10mg will be administered previous to apomorphine infusion making use of the apomorphine infusion system
Study: NCT04386122
Drug: JAPROLOX TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage: Single dose of one tablet of reference product in each period. Administration: 30 minutes before administration, subjects will receive a test meal (high-fat and high-calorie) and finish this meal in 30 minutes or less. Take 1 tablet of reference product with 240 mL of water. Lying position or strenuous activities are not allowed within 2 hours post dose
Study: NCT00326326
Drug: CP-778,875
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03962920
Drug: Tigecycline 50 MG
Normalized name: tigecycline 50 MG
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local instillation of drug directly to the tumour tissue
Study: NCT02179151
Drug: ZGN-440 Placebo for Injectable Suspension
Normalized name: placebo 440 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo twice weekly subcutaneous injections for up to 28 weeks.
Study: NCT01751919
Drug: Glivec film-coated tablet 100 mg, 4 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00751829
Drug: olmesartan medoxomil + hydrochlorothiazide, if necessary
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral olmesartan medoxomil tablets 20 mg or 40 mg once daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
Study: NCT00751829
Drug: nitrendipine + hydrochlorothiazide, if necessary
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral nitrendipine tablets 10 or 20 mg taken twice daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
Study: NCT00381095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00720434
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
Study: NCT00275054
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cycles 1-6: 250 mg/m² i.v., d2-4, q28d
Study: NCT00846430
Drug: Celecoxib (Celebrex)
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: age and weight dependant
Study: NCT00099853
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin matching placebo
Study: NCT00507962
Drug: Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose 20 mg/m\^2 IV On Day 1 Every 4 Weeks
Study: NCT00317213
Drug: LIBERTAL- a phospholipid mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01014585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets administered orally twice daily
Study: NCT02580331
Drug: SRP and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placement of placebo gel into classII furcation defects after scaling and root planing
Study: NCT02808390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID for 8 Weeks
Study: NCT04233060
Drug: CS3005
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS3005 will be orally administrated twice daily (BID) until PD, unacceptable toxicity, withdrawal of informed consent, or until maximum treatment duration per protocol (2 years)
Study: NCT00905541
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg/day
Study: NCT00905541
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg simvastatin acute-on-chronic
Study: NCT04174118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile normal saline (0.9% NaCL) matching volume of belcesiran doses will be administered subcutaneously (SC).
Study: NCT02935309
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pre-surgery Capecitabine, 850 mg/m\^2, twice a day (BID) on days 1-5 for 5½ -6 weeks.
Study: NCT03719157
Drug: intravenous patient controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were followed using a standardized postoperative analgesia protocol which includes tramadol PCA. Tramadol at a concentration of 5 mg/mL is included in our PCA protocol (total volume 100 mL.) PCAs were set to no basal infusion and 10 mg bolus doses with a 20 min lock time.
Study: NCT00456898
Drug: Codeine
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03256149
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (IV placebo)
Study: NCT06000514
Drug: Sm29 Protein, Schistosoma Mansoni
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sm29 cream twice a day in the ulcer(s), during 20 days; and Systemic IV Pentavalent antimony (Sbv) at 20mg/kg/day during 20 days.
Study: NCT03824912
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
Study: NCT04055233
Drug: NaCl; saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control arm: irrigation of subcutaneous tissue after fascia closure with NaCl (one minute) A single dose of perioperative antibiotics (cefuroxim alone or cefuroxim and metrodidazole in bowel surgeries) was given 30 minutes before skin incision.~Hair removal was done with electronic clippers and preoperative skin antisepsis was performed with propanol and povidone-iodine.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin.~Before closure of fascia, instruments and gloves were changed. No subcutaneous suture was used. Skin was closed either with skin staples, continuous intracutaneous suture or interrupted suture.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin.
Study: NCT02199899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03174236
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
Study: NCT00273013
Drug: GW274150
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW274150 will be available as 30 mg white oval tablets.
Study: NCT00273013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for Singulair and GW274150 will be available.
Study: NCT00235963
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003063
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003063
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01407094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-4 pills per day
Study: NCT02137967
Drug: 2.5% NaOCl
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01032148
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBH589 will be administered orally as once daily dose of 20 mg po q M, W, F on a q28 day cycle.
Study: NCT02901431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received a matching placebo orally. Approximate treatment duration was up to 24 weeks.
Study: NCT02901431
Drug: RO5285119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received age-adjusted total daily oral dose approximately equivalent to the adult doses of either 4 mg/d or 10 mg/d of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks (up to 52 additional weeks for those enrolled in the OLE).
Study: NCT03132584
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The chemotherapy drugs will be given in the hospital. During the first cycle of treatment, participants will stay in the hospital until their blood counts have recovered after treatment. During cycles 2 and 3, participants may go home after chemotherapy if they are doing well. The length of each cycle is 28 days~- Via IV Day 3
Study: NCT00935389
Drug: tripterygium glycosides
Normalized name: anthraquinone glycoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: The onset dosage should be 30mg/q.d. and can be reduced into 20mg b.i.d if CR obtained in 3 months. Without CR in 3 months, the dosage of 90mg/d will last for another 3 months and then reduced to 60mg/d.
Study: NCT01910675
Drug: FFP
Normalized name: ErgocaffPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 units Octaplas. Additional fibrinogen if needed.
Study: NCT00488787
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01260103
Drug: ANP Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of ANP therapy are administered for 52 weeks. If the study subject has an OR or maintains SD, ANP therapy is continued.
Study: NCT03849339
Drug: D635
Normalized name: FILTER,SUCTION DEVILBISS #7305D635
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug
Study: NCT03682497
Drug: AZD9977
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9977 capsules taken orally for 28 days.
Study: NCT03682497
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone tablets taken orally for 28 days.
Study: NCT01021540
Drug: Repository corticotrophin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acthar 80 IU SQ once a week and titrated up to twice a week
Study: NCT03515044
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered twice daily (BID)
Study: NCT00505843
Drug: MK0657
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7mg MK0657 capsules
Study: NCT03553186
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (200 cc sterile normal saline + placebo TXA ampule (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after pedicle screw instrumentation. Excess solution will be suctioned away using a non-cell saver suction.
Study: NCT02847598
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT00004059
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04233151
Drug: QL1203
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
Study: NCT04233151
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
Study: NCT04233151
Drug: mFOLFOX6 regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The mFOLFOX6 regimen is consist of oxaliplatin 85 mg/m\^2 intravenous (IV) infusion on Day 1;leucovorin, 200 mg/m\^2 on Days 1 and 5-fluorouracil 400 mg/m\^2 IV bolus on day 1, then 1200 mg/m\^2/dx2days(total 2400 mg/m\^2 over 46-48 hours) IV continuous infusion. Each cycle was 14 days.
Study: NCT01352689
Drug: CKD-828(FDC)
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
Study: NCT02309879
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in Remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
Study: NCT01138956
Drug: Pentavalent antimonial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent antimonial, 20mg/kg/day, 28 days, IV
Study: NCT00836355
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg orally once daily for 5 days
Study: NCT03036293
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral use.
Study: NCT03686397
Drug: SVT-15652
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 vial twice daily
Study: NCT03686397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 vial twice daily
Study: NCT01204138
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID
Study: NCT01469910
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending doses: 150 mg、225 mg、300 mg、400 mg、500 mg、600 mg、750 mg
Study: NCT00930059
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablets, every 12 hours for 12 wks
Study: NCT04799041
Drug: GTX 2/3
Approvals — FDA: no, EMA: no, PMDA: no
Description: There were 15 patients in this group. Each one received only one treatment.
Study: NCT04799041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: There were 15 patients in this group. Each one received only one treatment.
Study: NCT02399306
Drug: Enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the Trial Group received concurrent chemoradiotherapy and standardized, whole-course enteral nutrition management.
Study: NCT03660787
Drug: Seroguard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seroguard 0.41 g/L solution
Study: NCT03660787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT01542645
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl (12 mcg/kg) will be administered intraoperatively, with half of the dose given at induction of anesthesia (over 5 minutes) and the remainder administered as an infusion over the next 2 hours.
Study: NCT01538420
Drug: GLPG0492
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT01538420
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral solution
Study: NCT00213005
Drug: Carraguard (PC-515)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00283842
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00505843
Drug: Comparator: Placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7mg MK0657 Pbo capsules
Study: NCT00505843
Drug: Comparator: levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodopa \>/=1.0 mg/kg/hr dose of levodopa. levodopa infusions will occur over a 2 hour period
Study: NCT04013334
Drug: MTG201
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTG201, 3 x 10E12 vp delivered by intratumoral injection on days 1, 8, 22 and 50
Study: NCT03797196
Drug: standard dose tacrolimus with mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A standard Tacrolimus once-daily (Envarsus) regimen in combination with Everolimus will be evaluated in elderly transplant recipients
Study: NCT03634735
Drug: Thiamine
Normalized name: Thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamine B1
Study: NCT01238679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT02254486
Drug: NER1006
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
Study: NCT01176981
Drug: High Dose Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be given by IV at a dose of 12 gram/m2/dose.~The patient will receive 4-6 hours of hydration with alkalinization, and then HD MTX will be infused over 4 hours. Following this, the patient will be discharged home to receive continuous intravenous hydration through a portable pump. The patient will return to hospital daily for a comprehensive clinical assessment, IV hydration and antiemetics, MTX level and creatinine monitoring until MTX is cleared (3-4 days).
Study: NCT01151696
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00904280
Drug: Oxymorphone ER
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open label
Study: NCT01445860
Drug: Simvastatin/PF-03882845
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose 20 mg simvastatin on Day 1, 30 mg PF-03882845 once daily from Days 2 to 13, the single dose 20 mg simvastatin on Day 12.
Study: NCT02340962
Drug: TG-2349
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG-2349 (Furaprevir) is available as a Swedish orange capsule (size 0) for oral administration. Each capsule contains an equivalent of 100 mg of TG-2349 spray dried solid (SDD) and the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, and colloidal silicon oxide.
Study: NCT02115152
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02132104
Drug: Femoston
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormones treatment after surgery.
Study: NCT02421341
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During study visits 2 and 3 you will receive an intrathecal (fluid filled space surrounding the spinal cord) injection of either fentanyl or placebo (saline). Fentanyl is an opiate (narcotic) drug and a common medication, however the way fentanyl is being used in this study is considered investigational.
Study: NCT02421341
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02115152
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02115152
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01320722
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo soft gel once per week for 8 weeks
Study: NCT01320722
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total)
Study: NCT02343484
Drug: Gelified ethanol combined to pulsed radiofrequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gelified ethanol (Discogel) is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally. Pulsed radiofrequency treatment is performed intradiscally for the management of chronic discogenic low back pain. The intradiscal pulsed radiofrequency is first applied and then combined to gelified ethanol injection via the same radiofrequency needle.
Study: NCT02343484
Drug: Gelified ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gelified ethanol is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally.
Study: NCT00936624
Drug: SOTB07
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOTB07 100mg
Study: NCT00936624
Drug: SOTB07
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOTB07 200mg
Study: NCT00936624
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04480281
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in Group Placebo received an equal bolus volume of normal saline solution at induction, and then a continuous infusion started before surgical incision and maintained up until 24h postoperatively
Study: NCT03436719
Drug: Oral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole - 500 mg and Erythromycin - 500 mg per os \*3 times at 5 p.m.; 8 p.m., 11 p.m. in a day before surgery